SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.810
+0.190 (5.25%)
At close: Aug 25, 2026, 4:00 PM EDT
3.880
+0.070 (1.84%)
After-hours: Aug 25, 2026, 4:51 PM EDT
SAB Biotherapeutics Employees
SAB Biotherapeutics had 86 employees as of December 31, 2025. The number of employees increased by 23 or 36.51% compared to the previous year.
Employees
86
Change (1Y)
23
Growth (1Y)
36.51%
Revenue / Employee
n/a
Profits / Employee
-$253,346
Market Cap
346.66M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 86 | 23 | 36.51% |
| Dec 31, 2024 | 63 | 6 | 10.53% |
| Dec 31, 2023 | 57 | 1 | 1.79% |
| Dec 31, 2022 | 56 | -83 | -59.71% |
| Mar 31, 2022 | 148 | 62 | 72.09% |
| Dec 31, 2021 | 139 | 53 | 61.63% |
| Sep 30, 2021 | 143 | 57 | 66.28% |
| Jun 30, 2021 | 137 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Abeona Therapeutics | 226 |
| ProQR Therapeutics | 187 |
| Sutro Biopharma | 128 |
| Orchestra BioMed Holdings | 86 |
| Agenus | 81 |
| Immuneering | 57 |
| Vicore Pharma Holding AB | 40 |
SABS News
- 19 days ago - SAB Biotherapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 19 days ago - SAB Biotherapeutics Earnings release: Q2 2026 - Filings
- 19 days ago - SAB Biotherapeutics Quarterly report: Q2 2026 - Filings
- 19 days ago - SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - GlobeNewsWire
- 26 days ago - SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET - GlobeNewsWire
- 7 weeks ago - Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes - GlobeNewsWire
- 2 months ago - SAB Biotherapeutics initiated with an Overweight at Barclays - TheFly
- 3 months ago - SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - GlobeNewsWire